ZymoGenetics (ZGEN) Files to Sell Up to $100M of Common Stock
More News related to ZGEN
- Morning Movers 11/06: ACLS, CVM, ZIOP, LPSN, CABL, ZGEN Higher; NHWK, GOK, CROX, CVI, RAIL, CSTR Lower
- Wedbush Upgrades ZymoGenetics (ZGEN) to Outperform; Believe ZGEN on Track to Meet 2010 Sales Estimates
- ZymoGenetics (ZGEN) Reports Q3 Loss of $0.17
- ZymoGenetics Reports Third Quarter 2009 Financial Results
- Trading Radar for 11/05: Starbucks (SBUX), CBS Corp. (CBS), CVS (CVS), Toyota (TM), Thomson Reuters (TRI)
More News related to Equity Offerings
- LTX-Credence (LTXC) Files $100 Mixed Shelf
- Metabolix (MBLX) Commences Common Stock Public Offering
- Praxair (PX) Prices $400M of 1.75% Notes
- General Cable (BGC) Extends Expiration Date of Its Convertible Note Exchange Offer
- First Defiance Financial (FDEF) Files $80M Shelf Registration
ZymoGenetics, Inc. (NASDAQ: ZGEN) today announced that it has filed a registration statement with the SEC. If and when the SEC declares the registration statement effective, it would allow the Company to offer and sell up to $100 million of its common stock, no par value per share, from time to time. The registration statement is intended to replace the Company's previously filed shelf registration statement, which will expire on December 1, 2008.
ZymoGenetics, Inc., a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of therapeutic proteins for the treatment of human diseases primarily hemostasis, inflammatory and autoimmune diseases, cancer, and viral infections.
Related Categories
Equity OfferingsStocks Mentioned
-0.06Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
